A Test for Relapse in Estrogen-receptor positive breast cancer using the expression status of few genes


Novel accelerated progression relapse test can separate patients with good prognosis from those with bad prognosis using an assay of four identified genes at a fraction of the cost of other methods.

Many breast cancer patienst will remain relapse-free even without chemotherapy, however, accepted clinico-pathological variables are unreliable indicators of prognosis. The novel accelerated progression relapse test separates patient with good prognosis from those with a poor prognosis using a simpe assay of four genes. It offers a test for relapse with power comparable to others on the market at a fraction of the cost.

Patent Information:
For Information, Contact:
Richard Cox
Director, Licensing & Business Development
University of Notre Dame
(574) 631-5158
Steven Buechler
© 2019. All Rights Reserved. Powered by Inteum